OBJECTIVE: The effect of pulse cyclophosphamide treatment was retrospectively assessed in 25 systemic lupus erythematosus (SLE) patients with central nervous system involvement. All patients who tested positive for anti-phospholipid antibodies and/or lupus anticoagulant were excluded. RESULTS: Low-dose intravenous cyclophosphamide pulses (500 mg) were administered weekly in all patients. Twenty-four out of 25 patients attained a good response (after a mean of 11 days). Cyclophosphamide was well tolerated in all patients with only minor side effects. None of the patients experienced ovarian failure, cystitis or herpes zoster. CONCLUSIONS: Weekly low-dose cyclophosphamide pulses appear to be safe and effective for the management of neuropsychiatric manifestations in SLE patients without antiphospholipid antibodies.
OBJECTIVE: The effect of pulse cyclophosphamide treatment was retrospectively assessed in 25 systemic lupus erythematosus (SLE) patients with central nervous system involvement. All patients who tested positive for anti-phospholipid antibodies and/or lupus anticoagulant were excluded. RESULTS: Low-dose intravenous cyclophosphamide pulses (500 mg) were administered weekly in all patients. Twenty-four out of 25 patients attained a good response (after a mean of 11 days). Cyclophosphamide was well tolerated in all patients with only minor side effects. None of the patients experienced ovarian failure, cystitis or herpes zoster. CONCLUSIONS: Weekly low-dose cyclophosphamide pulses appear to be safe and effective for the management of neuropsychiatric manifestations in SLEpatients without antiphospholipid antibodies.
Authors: E Svenungsson; M Andersson; L Brundin; R van Vollenhoven; M Khademi; A Tarkowski; D Greitz; M Dahlström; I Lundberg; L Klareskog; T Olsson Journal: Ann Rheum Dis Date: 2001-04 Impact factor: 19.103
Authors: L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela Journal: Ann Rheum Dis Date: 2005-04 Impact factor: 19.103
Authors: Boris Sakic; David L Kirkham; David A Ballok; James Mwanjewe; Ian M Fearon; Joseph Macri; Guanhua Yu; Michelle M Sidor; Judah A Denburg; Henry Szechtman; Jonathan Lau; Alexander K Ball; Laurie C Doering Journal: J Neuroimmunol Date: 2005-09-29 Impact factor: 3.478
Authors: Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah Journal: Cochrane Database Syst Rev Date: 2013-02-28